Baxdela Delafloxacin 300 mg Injection Powder Vial 10 Pack (RX)

Baxdela Delafloxacin 300 mg Injection Powder Vial is an antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. It's particularly effective against resistant strains like MRSA (Methicillin-resistant Staphylococcus aureus). As a fluoroquinolone antibiotic, Baxdela works by inhibiting bacterial DNA gyrase and topoisomerase IV, essential for DNA replication and repair. This broad-spectrum antibiotic is administered intravenously and helps reduce infection duration, alleviate symptoms, and prevent complications in serious bacterial infections.

Baxdela (Delafloxacin) 300 mg Injection Powder Vial by Melinta Therapeutics is an advanced fluoroquinolone antibiotic designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) in adults. This injectable formulation is particularly useful in hospital settings, allowing for effective management of severe infections where intravenous administration is required. Each box contains 10 vials, providing a suitable quantity for multiple dosing and patient management as determined by a healthcare provider.

Details and Features:

• Active Ingredient: Each vial contains delafloxacin 300 mg in powder form, which must be reconstituted for intravenous infusion.
  
• Packaging: Supplied in a pack of 10 vials, catering to needs in clinical and hospital environments.
  
• Spectrum of Activity: Effective against a broad range of gram-positive and gram-negative pathogens, including MRSA, providing comprehensive infection management.
  
• Administration: Intended for intravenous administration, suitable for patients who are unable to take oral medications or require immediate therapeutic intervention.
  
• Usage Indication: Approved for the treatment of ABSSSI and CABP caused by susceptible strains of bacteria.

Mechanism of Action:

Delafloxacin targets bacterial DNA replication enzymes, namely DNA gyrase and topoisomerase IV. By inhibiting these critical enzymes, it prevents DNA replication and transcription within the bacteria, leading to cell death. This dual mechanism of action contributes to its efficacy across a diverse range of bacterial pathogens.

Warnings:

• Hypersensitivity Reactions: Includes the risk of severe allergic reactions, such as anaphylaxis; thus, it should not be administered to patients with known allergy to fluoroquinolones.
  
• Tendinitis and Tendon Rupture: Increased risk, particularly in older adults or those on concurrent corticosteroid therapy.
  
• Peripheral Neuropathy: Potential for nerve damage which can be permanent; patients should be alerted to this risk and advised to report any symptoms of nerve dysfunction.
  
• CNS Effects: May cause central nervous system disturbances, including seizures, in predisposed individuals.
  
• Phototoxicity: Patients should avoid excessive sunlight or UV light exposure during treatment.
    
  Side Effects:
• Common Side Effects: Nausea, diarrhea, headache, and transaminase elevations.
  
• Serious Side Effects: Tendon rupture, peripheral neuropathy, CNS effects including seizures, serious hypersensitivity reactions, and Clostridium difficile-associated diarrhea.
  
• Gastrointestinal Effects: Potential for severe diarrhea indicative of Clostridium difficile infection requiring discontinuation and treatment.

Baxdela 300 mg Injection Powder Vial offers a powerful solution for managing serious bacterial infections in adult patients. Healthcare providers should ensure appropriate use by considering the risks, monitoring patients for adverse effects, and facilitating safe administration.